Page 10 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

BOR, best overall response; CR, complete response; CRR, complete response rate; PFS, progression-free survival.

The four patient clusters had several ALC, absolute lymphocyte count; CAR, chimeric antigen receptor; CD, cluster of differentiation; CRR, complete response rate; LDH,
differences in patient and manufacturing lactate dehydrogenase; Leuk, leukocyte; Mono, monocyte; mPFS, median progression-free survival; M-protein, monoclonal protein;
features (see Table). Patients with more PBMC, peripheral blood mononuclear cell; PI, proteosome inhibitor; sBCMA, serum B-cell maturation antigen; TI, topoisomerase
favourable clinical endpoints (those in inhibitor; VCN, vector copy number.
cluster 4) had a lower tumour burden,
higher starting lymphocyte count,
favourable prior exposures to select
therapies, longer washout period after
alkylator treatment, and a higher CAR T
cell yield compared to clusters 1 and 2.

The study authors concluded that select
variables using accessible laboratory or
medical history data, such as absolute
lymphocyte count (ALC) and time since
last exposure to alkylating agents,
can help identify RRMM patients who
may be at risk for low manufacturing
yield and less durable clinical efficacy,
and may help inform patients likely to
achieve improved outcomes with CAR T
cell therapy.

TABLE OF CONTENTS 10